StreetInsider.com News Articles

Cosmos Health unit signs 5.2M-unit deal with Target Pharma

Tue, 15 Sep 2026 10:31:36 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced that its subsidiary Cana Laboratories S.A. has secured five-year contract manufacturing agreements with Target Pharma covering approximately 5.2 million units, according to a company press release.

The agreements cover two products: Mupirocin, a topical antibiotic, at approximately 900,000 units annually, and Tretin, an isotretinoin-based acne treatment, at approximately 140,000 units annually. Combined, the contracts total roughly 1.04 million units per year over five years.

The new agreements bring Cana's cumulative orderbook to more than 32.7 million units, a 31% increase since June 2026. The company states that 7.7 million units were added in September alone, including

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

Tue, 15 Sep 2026 10:30:00 -0400

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today
Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma
Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026
Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows
Division targeted to generate over $10 million in recurring annual profit at full capacity

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

Tue, 15 Sep 2026 10:30:00 -0400

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today
Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma
Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026
Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows
Division targeted to generate over $10 million in recurring annual profit at full capacity

Cosmos Health plans tokenized IP financing for hydrogel weight-loss device

Mon, 14 Sep 2026 15:59:30 -0400

Cosmos Health Inc. (NASDAQ: COSM) has engaged Prime Ledger Inc., a digital asset advisory firm, to structure a tokenized financing backed by the intellectual property of CCX0722, an ingestible hydrogel-based medical device in development for weight management, according to a press release.

The proposed structure is designed to raise capital against CCX0722 and its underlying intellectual property without issuing new shares of Cosmos Health common stock. The company says it expects to retain the economic benefits of CCX0722, including future cash flows, under the proposed arrangement.

CCX0722 is being developed as a non-pharmacological medical device administered as a capsule before meals. The

Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market

Mon, 14 Sep 2026 15:59:00 -0400

Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock
Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets.
CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption
Intellectual property owned outright, with patent applications advanced into the United States, Europe, Australia and Canada
Addresses a global weight management market projected to reach $562.2 billion by 2033 (14.2% CAGR) - set against a broader tokenized real-world-asset market projected

Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market

Mon, 14 Sep 2026 15:59:00 -0400

Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock
Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets.
CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption
Intellectual property owned outright, with patent applications advanced into the United States, Europe, Australia and Canada
Addresses a global weight management market projected to reach $562.2 billion by 2033 (14.2% CAGR) - set against a broader tokenized real-world-asset market projected

Cosmos Health unit secures 2.5M-unit drug manufacturing deal with Viofar

Fri, 11 Sep 2026 11:11:12 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced that its wholly owned subsidiary, Cana Laboratories S.A., has signed a five-year contract manufacturing agreement with Viofar to produce approximately 2.5 million units of ROSARTIA, a rosuvastatin-based lipid-lowering medication.

Under the agreement, Cana will manufacture approximately 500,000 units annually across four dosage strengths: 5 mg, 10 mg, 20 mg, and 40 mg. Rosuvastatin belongs to the statin class of drugs and is used to manage elevated cholesterol and lipid disorders.

The new contract increases Cana's cumulative contract manufacturing orderbook to more than 27.5 million units, up from over 25 million units reported in June 2026.

Cana operates

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

Fri, 11 Sep 2026 11:10:00 -0400

500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories
Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio
Cumulative contract manufacturing orderbook increases to more than 27.5 million units, up from over 25 million units reported in June 2026
Further strengthens recurring cash flow visibility and expands Cana's long-term manufacturing relationships with established pharmaceutical companies

CHICAGO, IL / ACCESS Newswire / September 11, 2026 / Cosmos Health Inc. ("Cosmos Health"

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

Fri, 11 Sep 2026 11:10:00 -0400

500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories
Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio
Cumulative contract manufacturing orderbook increases to more than 27.5 million units, up from over 25 million units reported in June 2026
Further strengthens recurring cash flow visibility and expands Cana's long-term manufacturing relationships with established pharmaceutical companies

CHICAGO, IL / ACCESS Newswire / September 11, 2026 / Cosmos Health Inc. ("Cosmos Health"

Cosmos Health begins UK sales of veterinary antimicrobial C-ScrubVet

Wed, 09 Sep 2026 09:31:35 -0400

Cosmos Health Inc. (NASDAQ: COSM) has received its first orders for C-ScrubVet, a veterinary antimicrobial cleanser, with sales commencing in the United Kingdom, according to a company statement.
C-ScrubVet Wash 4% CHDG contains 4% chlorhexidine digluconate and is formulated for dogs, cats, horses, and companion and large animals. The product is supplied in a 500ml pump-dispenser bottle and is certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use.
The product is manufactured at Cana Laboratories, the company's EU GMP-licensed and EMA-certified facility in Athens, Greece. Cosmos Health describes C-ScrubVet as an extension of its

Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

Wed, 09 Sep 2026 09:30:00 -0400

First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet
Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle
Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026
Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinics
Certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use
Manufactured in-house at Cana Laboratories' EU GMP-licensed, EMA-certified facility, consistent with the Company's vertically integrated model
Extends

Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

Wed, 09 Sep 2026 09:30:00 -0400

First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet
Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle
Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026
Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinics
Certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use
Manufactured in-house at Cana Laboratories' EU GMP-licensed, EMA-certified facility, consistent with the Company's vertically integrated model
Extends

Cosmos Health reports record revenue, retires debt early in 2026

Thu, 03 Sep 2026 09:33:17 -0400

Cosmos Health Inc. (NASDAQ: COSM) issued a corporate update covering operational and financial developments from January through August 2026, reporting record revenue across three consecutive periods and early retirement of an $8 million convertible note.
The company reported first-half 2026 revenue of $36.91 million, a 29.7% increase year-over-year, following full-year 2025 revenue of $65.27 million, which was up 20% from the prior year. Q1 2026 revenue was $17.93 million and Q2 2026 revenue was $18.99 million. The company's annualized adjusted run-rate is stated to exceed $75 million, with full-year 2026 guidance set at more than $90 million.
On Aug. 28, 2026, the

Cosmos Health: A Company Transformed — 2026 Year-to-Date

Thu, 03 Sep 2026 09:30:00 -0400

Record Revenue Across All Quarters Reported. Balance Sheet Deleveraged. Capital Structure Streamlined. Proprietary IP Filed in Four Global Markets. U.S. Market Entered. Global rollout of proprietary brands continues. Share repurchases underway. Reaffirms Guidance Targets
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026

Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M. Full-year 2026 guidance: $90M+.
ATW $8M convertible note retired 12 months early: No further conversions, no dilution.
Strengthened balance sheet: H1 2026 total liabilities reduced 13.3%

Cosmos Health: A Company Transformed — 2026 Year-to-Date

Thu, 03 Sep 2026 09:30:00 -0400

Record Revenue Across All Quarters Reported. Balance Sheet Deleveraged. Capital Structure Streamlined. Proprietary IP Filed in Four Global Markets. U.S. Market Entered. Global rollout of proprietary brands continues. Share repurchases underway. Reaffirms Guidance Targets
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026

Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M. Full-year 2026 guidance: $90M+.
ATW $8M convertible note retired 12 months early: No further conversions, no dilution.
Strengthened balance sheet: H1 2026 total liabilities reduced 13.3%

Cosmos Health retires $8M convertible note a year early, buys back stock

Fri, 28 Aug 2026 09:30:35 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced it has retired an $8.0 million senior secured convertible note issued to ATW in August 2025, twelve months before its August 2027 maturity date, according to a company statement.
The note carried a 9% coupon. Its early retirement eliminates future share conversions and associated dilution. The company said total liabilities fell $6.27 million, or 13.3%, in its second quarter, while stockholders' equity rose 12.2% and its liabilities-to-assets ratio improved by 550 basis points.
Cosmos Health also disclosed it has withdrawn its registration statements on Form S-1 and Form S-3, leaving no effective shelf registration statement or

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

Fri, 28 Aug 2026 09:30:00 -0400

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution
Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor
Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control
Strong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength
$5.0 million share repurchase program underway, following record

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

Fri, 28 Aug 2026 09:30:00 -0400

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution
Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor
Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control
Strong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength
$5.0 million share repurchase program underway, following record

Cosmos Health projects $6M in annual revenue from new olive supplement

Mon, 24 Aug 2026 15:40:28 -0400

Cosmos Health Inc. (NASDAQ: COSM) has announced projections that its Oliv18™ product will generate more than $6 million in incremental annual U.S. revenue within 12 to 18 months, with an estimated $4.3 million in gross profit at an approximately 72% gross margin.
Oliv18™ is a whole olive polyphenol formulation that is USDA and EU organic certified and produced through a solvent-free process. The product is part of the company's "18 Series" nutraceutical portfolio and is being introduced in the U.S. cardiovascular health and antioxidant supplement categories.
According to the company, the rollout will begin with direct-to-consumer e-commerce, with planned expansion into retail

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Mon, 24 Aug 2026 15:40:00 -0400

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%.

Oliv18™ is part of the Company's "18 Series," a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Mon, 24 Aug 2026 15:40:00 -0400

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%.

Oliv18™ is part of the Company's "18 Series," a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Mon, 24 Aug 2026 15:40:00 -0400

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%.

Oliv18™ is part of the Company's "18 Series," a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Mon, 24 Aug 2026 15:40:00 -0400

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%.

Oliv18™ is part of the Company's "18 Series," a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced

Form 8-K Cosmos Health Inc. For: Aug 19

Thu, 20 Aug 2026 17:11:00 -0400
si-local-file:///var/storage/secattach/20260820/26957150.html

Form 8-K Cosmos Health Inc. For: Aug 19

Thu, 20 Aug 2026 17:11:00 -0400
si-local-file:///var/storage/secattach/20260820/26957150.html